Clinical and immunologic implications of COVID-19 in patients with melanoma and renal cell carcinoma receiving immune checkpoint inhibitors
Affiliation
Department of Medicine, Roswell Park Comprehensive Cancer Center, Buffalo, New York, USA.Issue Date
2021
Metadata
Show full item recordAbstract
The clinical and immunologic implications of the SARS-CoV-2 pandemic for patients with cancer receiving systemic anticancer therapy have introduced a multitude of clinical challenges and academic controversies. This review summarizes the current evidence, discussion points, and recommendations regarding the use of immune checkpoint inhibitors (ICIs) in patients with cancer during the SARS-CoV-2 pandemic, with a focus on patients with melanoma and renal cell carcinoma (RCC). More specifically, we summarize the theoretical concepts and available objective data regarding the relationships between ICIs and the antiviral immune response, along with recommended clinical approaches to the management of melanoma and RCC patient cohorts receiving ICIs throughout the course of the COVID-19 pandemic. Additional insights regarding the use of ICIs in the setting of current and upcoming COVID-19 vaccines and broader implications toward future pandemics are also discussed.Citation
Switzer B, Haanen J, Lorigan PC, Puzanov I, Turajlic S. Clinical and immunologic implications of COVID-19 in patients with melanoma and renal cell carcinoma receiving immune checkpoint inhibitors. J Immunother Cancer. 2021 Jul;9(7):e002835.Journal
Journal for Immunotherapy of CancerDOI
10.1136/jitc-2021-002835PubMed ID
34272309Additional Links
https://dx.doi.org/10.1136/jitc-2021-002835Type
OtherLanguage
enae974a485f413a2113503eed53cd6c53
10.1136/jitc-2021-002835
Scopus Count
Collections
Related articles
- Case Report: Clinical Management of a Patient With Metastatic Non-Small Cell Lung Cancer Newly Receiving Immune Checkpoint Inhibition During Symptomatic COVID-19.
- Authors: Mellinghoff SC, Vanshylla K, Dahlke C, Addo MM, Cornely OA, Klein F, Persigehl T, Rybniker J, Gruell H, Bröckelmann PJ
- Issue date: 2021
- Beyond conventional immune-checkpoint inhibition - novel immunotherapies for renal cell carcinoma.
- Authors: Braun DA, Bakouny Z, Hirsch L, Flippot R, Van Allen EM, Wu CJ, Choueiri TK
- Issue date: 2021 Apr
- Indications for and contraindications of immune checkpoint inhibitors in cancer patients with COVID-19 vaccination.
- Authors: Luo B, Li J, Hou X, Yang Q, Zhou Y, Ye J, Wu X, Feng Y, Hu T, Xu Z, He Y, Sun J
- Issue date: 2021 Sep
- Immune checkpoint inhibitors increase T cell immunity during SARS-CoV-2 infection.
- Authors: Yatim N, Boussier J, Tetu P, Smith N, Bruel T, Charbit B, Barnabei L, Corneau A, Da Meda L, Allayous C, Baroudjian B, Jebali M, Herms F, Grzelak L, Staropoli I, Calmettes V, Hadjadj J, Peyrony O, Cassius C, LeGoff J, Kramkimel N, Aractingi S, Fontes M, Blanc C, Rieux-Laucat F, Schwartz O, Terrier B, Duffy D, Lebbé C
- Issue date: 2021 Aug
- Overlap of immunotherapy-related pneumonitis and COVID-19 pneumonia: diagnostic and vaccine considerations.
- Authors: Abid MB
- Issue date: 2021 Apr